CARC-6/PanNET-7

Internal Request: Institutional review comment to review data for the inclusion of lanreotide.

External requests: Submission from Ipsen Biopharmaceuticals Inc. to consider the inclusion of lanreotide for the management of locoregional unresectable disease and/or distant metastases, symptomatic and asymptomatic, with low tumor burden or clinically significant tumor burden, for both carcinoid tumors and pancreatic neuroendocrine tumors.

Based on the data in the noted references and discussion, the panel consensus was to add lanreotide. This regimen was added with a category 2A recommendation for the following indications:

- **Neuroendocrine Tumors of the GI Tract, Lung and Thymus (Carcinoid Tumors)**
  - Management of unresectable locoregional disease and/or distant metastases for asymptomatic/low tumor burden, clinically significant tumor burden, carcinoid syndrome, and clinically significant progressive disease (CARC-6)
  - Treatment of Zollinger-Ellison syndrome in patients with gastric neuroendocrine tumors (CARC-4)

- **Neuroendocrine Tumors of the Pancreas**
  - Consider for symptom control in patients with locoregional gastrinomas. (PanNET-2)
  - For symptom control in patients with locoregional glucagonomas or VIPomas. (PanNET-4; PanNET-5)
  - For the management of locoregional unresectable disease and/or distant metastases (PanNET-7):
    - Consider for asymptomatic, low tumor burden, and stable disease.
    - For the treatment of symptomatic, clinically significant tumor burden, or clinically significant progressive disease.

References:


<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion</th>
<th>References</th>
<th>Vote</th>
</tr>
</thead>
</table>